Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
ASTER trial of abelacimab versus apixaban in cancer-associated VTE
NL-OMON51481Phase 3Recruiting
- Sponsor
- Anthos Therapeutics
- Start
- Feb 2023
- Modality
- Small Molecules, Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial in venous thromboembolism (VTE), deep vein thrombosis (DVT) and pulmonary embolism (PE) comparing Abelacimab with Apixaban (2 arms). Primary endpoint: Recurrent venous thromboembolism at 6 months. Started Feb 2023; status: recruiting.
02
Drugs
abelacimabapixaban
03
Conditions
venous thromboembolism (VTE)deep vein thrombosis (DVT)pulmonary embolism (PE)
Beyond the preview
Go deeper on NL-OMON51481.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NL-OMON51481.